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Abstract: Vitamin D receptor ligands have potential for the
treatment of hyperproliferative diseases and disorders related
to the immune system. However, hypercalcemic effects limit
their therapeutical uses and call for the development of
tissue-selective new analogs. We have designed and synthe-
sized the first examples of 1α,25-dihydroxyvitamin D3 analogs
bearing an allenic unit attached to the D ring to restrict the
side-chain conformational mobility. The triene system was
constructed by a Pd0-mediated cyclization/Suzuki-Miyaura
cross-coupling process in the presence of an allenic side
chain. The allenic moiety was built through an orthoester-
Claisen rearrangement of a propargylic alcohol. The biological
activity and structure of (22S)-1α,25-dihydroxy-17,20-dien-24-
homo-21-nor-vitamin D3 bound to binding domain of the
vitamin D receptor, provide information concerning side-
chain conformational requirements for biological activity.
Introduction
The active form of the secosteroid hormone vitamin D3, 1α,25-
dihydroxyvitamin D3 [1, calcitriol, 1,25-(OH)2D3, 1,25D, Figure 1],
exerts its biological functions by binding to the vitamin D
receptor (VDR), a transcription factor of the nuclear receptor
superfamily (NRs).[1] 1,25D was known for many years as a
primary regulator of calcium homeostasis, but it also controls a
wide range of other biological functions including cell differ-
entiation, cell proliferation, and immune responses.[2,3] 1,25D
induces the expression of more than 200 genes associated with
several diseases such as arthritis, diabetes and cancer, suggest-
ing that this secosteroid hormone might induce a wide range of
biological functions.[4] Unfortunately, 1,25D induces hypercalce-
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Figure 1. Structures of the natural hormone 1,25D (1), 1,25D analogs 2a–2e,
calcipotriol and maxacalcitol.
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mia at the doses required for the treatment of hyperprolifer-
ative diseases such as cancer.[3] This limitation has led to intense
synthetic efforts towards VDR ligands with selective activities as
potential therapeutic agents for the treatment of cancer,
immunodeficiency syndromes, autoimmune diseases and skin
disorders.[5] Calcipotriol and maxacalcitol, examples of 1,25D
analogs with a modified side-chain, exhibit similar or higher
antiproliferative potency with reduced calcemic effects in
comparison with natural hormone 1,25D (Figure 1).[6] Other
potent 1,25D analogs structurally modified at the CD-rings or
triene system that induce low potency for calcium metabolism
have also been synthesized. Representative examples of these
compounds include inecalcitol (19-nor-14-epi-23-yne-1,25D,
TX522)[7] and PG-136,[8] which exhibit anticancer properties, and
paricalcitol (19-nor-1,25D), which induces immunomodulatory
effects and was recently proposed as a therapeutic option for
patients with severe COVID-19.[9] Unfortunately, the mechanism
underlying the dissociation of the antiproliferative effects from
the calcemic effects, as well as the conformational requirements
for selective biological functions, have not yet been
established.[10]
The crystallographic structures of 1,25D and various of its
analogs in complex with the VDR ligand binding domain
indicate that the corresponding side-chain-C25OH groups
adopt similar positions.[11] However, the side-chain flexibility
makes difficult to predict the conformation associated with a
particular biological function. Okamura and coworkers, in efforts
to understand structure-activity relationships, pioneered the
synthesis of 1,25D analogs with rigid structural units at the side
chain to restrict its conformational mobility.[12] In the search for
vitamin D analogs with an even higher degree of restricted
mobility of the side chain, we have started a research program
on the synthesis and biological evaluation of 1,25D analogs
with locked units at the side chains attached to the D-ring, in
the form of double bond,[13] cyclopropane ring,[14] aromatic
ring,[15] and triple bond.[16] In connection with this program, we
describe here the development of the first side-chain analogs of
1,25D that incorporate an allenic unit at C17 as the structural
element to impart restricted mobility to the side chain.
Results and Discussion
Design
Based on the crystal structure of the active hVDR ligand-binding
domain (LBD) bound to 1,25D,[11a] we studied the docking of the
analogs 2a–2e bearing an allenic unit at the side chain
attached to C17 of the D-ring (Figure 1). We showed that analog
2d binds well (97%) to the VDR LBD in comparison with the
native hormone 1,25D (100%) (Figure 2). This analog adopts the
canonical active conformation as the natural hormone in the
binding pocked, where the A, C and D rings, and the triene
system occupy similar positions. The A-ring and side-chain
hydroxyl groups form effective hydrogen bonds with the same
amino acid residues (His-305, His-397, Ser-278, Arg-274, Tyr-143,
Ser-237) as the natural hormone. The other allenic analogs 2a
(87%), 2b (92%), 2c (86%), and 2e (84%) bind to the hVDR
LBD less efficiently than 2d. On the basis of the in silico binding
results, we chose compounds 2a, 2b and 2d as the synthetic
targets.
Retrosynthetic analysis of target compounds
The synthetic plan for the synthesis of target compounds 2a,
2b, and 2d is outlined in Scheme 1. The formation of the
vitamin D triene system involves a stereoselective Pd0-catalyzed
ring closure of enoltriflate 4 and subsequent Suzuki-Miyaura
coupling with unprotected alkenyl-boronic ester 3 in protic
medium following procedures developed in this laboratory.[17]
At this point, the stability of the allenic unit under the Pd-
catalyzed reaction conditions was uncertain. The boronates 3
are envisaged to arise from the allene 5 by conventional
Figure 2. A) Structure of the natural hormone 1,25D (yellow) in complex with hVDR LBD (PDB ID: 1DB1). B) Docked structure of analog 2d (magenta) into the
hVDR LBD. C) Superimposition of both 1,25D and 2d. Ligand-amino acid distances are shown in Å.
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chemistry. The key allene 5 would arise from propargylic
alcohol 6 through an orthoester-Claisen rearrangement.[18]
Compound 6 would be prepared in several steps by degrada-
tion of vitamin D2.
[19]
Synthesis of the upper boronate fragments
The synthesis of boronates 3a, 3b, and 3d is outlined in
Scheme 2. Reaction of ketone 7 with lithium trimeth-
ylsilylacetylide in THF followed by desilylation with Na2CO3 in
methanol provided propargylic alcohol 6[20] in 86% yield.
Exposure of 6 to orthoester Claisen rearrangement with triethyl
orthoacetate and acetic acid delivered the (S)-allene 5 (84%) as
a single isomer [1H NMR δ 5.27 (C=C=CH)]. Treatment of 5 with
methyl magnesium bromide in THF provided the tertiary
alcohol 8a (98%), which was deprotected to alcohol 9a (98%)
with tetrabutylammonium fluoride in THF. Pyridinium dichro-
mate oxidation of 9a in CH2Cl2 followed by Wittig-olefination of
the resulting ketone 10a with ylide Ph3P=CHBr,[21] prepared
from (Ph3PCH2Br)Br and KOtBu in toluene, led to (E)-alkenyl
bromide 11a in 69% yield (two steps), which was converted to
the desired upper boronate 3a (58% yield) without protection
of the side-chain-hydroxyl group by Miyaura’s modified
method[17,22] using bis(pinacolato)diboron and KOAc in the
presence of catalytic [1,1’bis(diphenylphosphino) ferrocene]
dichloropalladium(II) in DMSO.
The synthesis of boronate 3d began with ester 5, which was
converted to iodide 13 by a three steps sequence (81% yield)
involving reduction with diisobutylaluminum hydride in THF,
treatment of the resulting alcohol 12 with p-toluenesulfonyl
chloride in pyridine, and subsequent reaction of the resulting
Scheme 1. Retrosynthesis of target analogs 2a, 2b, and 2d from enoltriflate
4 and propargylic alcohol 6.
Scheme 2. Synthesis of the upper boronates 3a, 3b, and 3d.
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tosylate with sodium iodide in acetone. Chain extension by
reaction of iodide 13 with the lithium anion derived from tert-
butyl acetate in THF provided ester 14 in 95% yield, which was
converted to diol 16 (90%) by methylation (MeLi, THF) and
subsequent deprotection (nBu4NF, THF). Pyridinium dichromate
oxidation of 16 in CH2Cl2 and subsequent Wittig-olefination of
the resulting ketone 17 with ylide Ph3P=CHBr afforded the (E)-
alkenyl bromide 18 in 82% yield (two steps), which was
transformed into the desired upper boronate 3d (57% yield) by
reaction with bis(pinacolato)diboron and KOAc in the presence
of catalytic [1,1’bis(diphenylphosphino) ferrocene] dichloropal-
ladium(II) in DMSO as above (23.3% overall yield from ketone 7,
12 steps). The allene moiety survived the Pd-catalyzed process
during the formation of the vitamin D triene system though in
moderate yield.[23]
Synthesis of target compounds
With the upper fragments in hand, we proceeded to the final
convergent formation of the triene system of the target
compounds 2a, 2b, and 2d (Scheme 3). Pd-catalyzed carbocyc-
lization of enoltriflate 4 (1.1 equiv) and subsequent Suzuki-
Miyaura coupling with boronate 3a (1 equiv) in the presence of
catalytic bis(triphenylphosphine)palladium(II) in aqueous K3PO4
(2 M)/THF provided, after deprotection, the desired 1,25D-
analog 2a in 51% yield (two steps) (13.7% overall yield from
ketone 7, 14 steps). Same procedure was used for the
preparation of allenic analog 2b (16.4% overall yield from
ketone 7, 14 steps). In a similar way, Pd-catalyzed carbocycliza-
tion/Suzuki-Miyaura cross coupling tandem process on 3c
provided the protected 1,25D-analog 19, which upon desilyla-
tion, gave the desired allenic 1,25D-analog 2d (54%, two steps)
(14.5% overall yield from ketone 7, 14 steps).
Functional activity
As the in silico data indicate that the allene 2d binds to VDR
with the highest efficiency, we determined its biological proper-
ties. Transactivation assay in HeLa cells transfected with human
full length VDR showed that 1,25D (1) and 2d induce the
expression of a luciferase reporter gene under the control of
the promoter of human CYP24A1, the main vitamin D target
gene (Figure 3, A). Note that at lower doses, 2d was less potent
than 1. In addition, we monitor the expression of CYP24A1
transcripts in cells derived from prostate cancer metastasis (DU-
145) treated for 24 h. Ligands 2d and 1 induced transcript
levels at 100 nM and 10 nM, but the levels were lower in cells
treated with 2 (Figure 3, B).
To determine the effects of 2d in vivo, wild type mice were
daily treated with various doses of 2d and 1 for 5 days. In
agreement with previous results,[24] 1 μg/kg of 1 induced
hypercalcemia and the transcript levels of the vitamin D target
genes Cyp24a1 and S100g in the kidney (Figure 3, D–E).
However, the renal transcript levels were similar in mice treated
with 2d and with vehicle (Figure 3, D–E). The calcemic activity
of 2d was evaluated by monitoring the serum calcium levels in
the treated mice (Figure 3, C). Serum calcium levels were
unaffected at 1 and 3 μg/kg. Thus, these results indicate that
2d is less potent than 1,25D, but behaves as a low-calcemic
1,25D analog.
Crystal structure
To determine the binding pose of the analog 2d, we co-
crystallized the zebrafish wild-type VDR LBD[11c] in complex with
Scheme 3. Synthesis of the target vitamin D analogs 2a, 2b, and 2d.
Figure 3. A) Transactivation assay in HeLa cells, transfected with full-length
human VDR and a luciferase reporter gene under the control of the human
CYP24A1 promoter, and treated for 24 h with 1,25D (1) or 2d at various
concentrations. B) CYP24A1 transcript levels in DU-145 cells treated for 24 h
with 1 or 2d at various concentrations. EtOH was used as solvent (  ). Serum
calcium levels (C) and renal transcript levels of Cyp24a1 (D) and S100g (E)
determined in wild type mice, 6 h after 5 daily administrations of 2d or 1 at
the indicated doses. Oil was used as vehicle (0 or -). *p<0.05 vs. vehicle.
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the ligand and a coactivator peptide and solved the structure
with a resolution up to 2.1 Å (Supporting Table 1). The overall
structure is highly homologous to the VDR-1,25D structure with
a root mean square deviation of 0.3 Å over 235 residues when
comparing the Cα atoms of the two complexes. Superposition
of the VDR ligand binding pocket in the presence of 2d and
1,25D shows similar positioning of the ligands (Figure 4, A), in
agreement with the in silico docking data. The C1-OH, C3-OH
and C25-OH groups of 2d form similar H-bonds as 1,25D
(Figure 4A), however the C25-OH forms weaker H-bonds with
His-333 and His-423 (3.2 Å and 3.0 Å for analog 2d compared to
2.8 Å and 2.8 Å for 1,25D). The secosteroidal part of the ligand
forms similar interactions with the zVDR ligand binding pocket
compared to 1,25D. The side chain of 2 forms extensive
interactions with Leu-255, Leu-258, Val-262, Ala-331, His-333,
His-423, Tyr-427, Leu-430 at a 4.0 Å distance cutoff (Figure 4, B).
The difference in side chain position as a consequence of the
rigid allenic unit attached to C17, results in a loss of interaction
to residue Leu-337 in complex with 2d. Overall, the contacts
formed by 2d in the zVDR complex stabilize the agonist
conformation of VDR in agreement with the agonist potency of
this novel compound. The weaker hydrogen bonds with His-
333 and His-423 and loss of interaction with Leu-337 explain
the observed difference in activity between the 1,25D and
compound 2d.
Conclusion
In summary, we have designed and synthesized three analogs
of the hormone 1α,25-dihydroxyvitamin D3 bearing an allenic
unit attached to C17 as the structural element to impart
conformational rigidity near the D-ring. Highlights of the
synthetic route (about 14% overall yield from bicyclic ketone 7,
14 steps), include the access to the allenic moiety by an
orthoester-Claisen rearrangement and the formation of the
triene system by a Pd0-catalyzed cyclization/cross coupling
process involving an enoltriflate, precursor of the A-ring, and a
vinyl boronate containing an allenic side-chain unit correspond-
ing to the CD-Side chain framework. Biological evaluation of 2d
with the highest affinity for VDR, reveals that the geometry
imposed by the C17-allene moiety reduces the transcriptional
potency and calcemic activity. The crystallographic structure of
2d in complex with the VDR LBD provides information
concerning side-chain conformational requirements for the
design of new noncalcemic vitamin D analogs of potential
therapeutic interest.
Experimental Section
General: For details on the general materials and methods, see
Supporting Information.
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